glutathione reductase antioxidant pathway mediated by in response to glutathione reduced vs oxidized structure

WADA Prohibition The World Anti-Doping Agency explicitly prohibits AOD-9604 for competitive athletes: Listed under Section S0 (Non-Approved Substances) and S2.2.3 (Growth Hormone Fragments) Prohibited at all times (both in-competition and out-of-competition) No Therapeutic Use Exemptions (TUEs) available Detection methods developed and implemented in anti-doping laboratories worldwide WADAs 2013 statement clarified that AOD-9604 is a substance still under pre-clinical and clinical development and has not been approved for therapeutic use by any government health authority in the world. Research Classification: AOD-9604 is available only for laboratory research use

Additionally, research suggests that semaglutide may also reduce A1C levels in people with or without diabetes, making it a dual-purpose treatment [5]

[5] This supports a distinction between AOD9604 and full-length hGH in the specific receptor-binding and proliferation assays used

Obesity (Silver Spring) 2023;31:35062.PubMedPMC 44

The reconstitution technique is identical regardless of the source